CTOs on the Move

Family Service Association of Bucks County

www.fsabc.org

 
Family Service offers a variety of programs and services focused on increasing opportunities for adults, protecting seniors, reducing substance abuse, improving the lives of those with mental illness, preparing children and adolescents for the future, ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.fsabc.org
  • 4, Cornerstone Drive
    Langhorne, PA USA 19047
  • Phone: 215.757.6916

Executives

Name Title Contact Details

Similar Companies

The Macroflux

The Macroflux Corp. is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.

Hi-School Pharmacy

Hi-School Pharmacy is a Vancouver, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ipsen

Ipsen S.A. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.